digipharm®
Home •  Site Map  •  Research  •  Reports  •  International Experts  •  Music Preparations  •  Fundamentals  •  News  •  Questions  •  Shop
digipharm®
peter huebner • micro music laboratories
M E D I C A L   R E S O N A N C E   T H E R A P Y   M U S I C®
R E D U C T I O N   O F   P S Y C H O – P H Y S I O L O G I C A L   M A N I F E S T A T I O N S   O F   S T R E S S

SCIENTIFIC RESEARCH

Research Fields Summary

Headaches

Migraine

Sleep Disorders

Pains

Neurodermatitis

Psoriasis

Medication Consumption

Dermatology

Dispersion of Stress

Faster Recovery

Mental Distress / Fear

Dizziness

Cardiovascular System

Hormone / Immune System

The Mental State

Operations

Radiation Sickness

ENT

Multiple Sclerosis

Gerontology

Diabetes

Cerebral & Nervous System

Mental & Sensory Abilities

Pediatrics

Pregnancy & Birth

Gynecology

Epilepsy

Concentration / Memory

Courage to Face Life

Creativity

Harmony

Mother & Child

Neurophysiological &
Sensory Disorders

Relaxation

Vital Energy

 

 






Scientific Studies and Clinical Observations
DERMATOLOGY
  • Lowering of the blood-pressure in patients with neurodermatitis and psoriasis: on the first day the average levels in the experimental groups (neurodermatitis and psoriasis) fell from 130/85 mm Hg prior to listening, to 125/80 mm Hg after listening, and this was repeated on the third and sixth day. On the fourteenth day the levels fell from 130/85 mm Hg prior to listening, to 120/70 mm Hg after listening.
  • Reduction of the heart rate in neurodermatitis and psoriasis patients: prior to the auditory training, the mean heart rate stood at circa 85 beats per minute. After the first day of the auditory training, heart rates had fallen by an average of 5 beats per minute, and this was repeated on the third day. On the sixth day the heart rate fell by an average of 10 beats per minute. After completion of the auditory training on the fourteenth day, the average heart rate after listening averaged 70 beats per minute.
    The heart rate in the control groups did not change.


  For this indication please use the program:

NEURODERMATITIS
PSORIASIS
 
 
 

   If you want to look at the studies in detail, please visit:

With kind permission of AAR EDITION INTERNATIONAL
© 1998-  DIGIPHARM >